Literature DB >> 14974876

The NICE reference case requirement: implications for drug manufacturers and health systems.

Paul C Langley.   

Abstract

Mesh:

Year:  2004        PMID: 14974876     DOI: 10.2165/00019053-200422040-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  4 in total

1.  An empirical comparison of EQ-5D and SF-6D in liver transplant patients.

Authors:  Louise Longworth; Stirling Bryan
Journal:  Health Econ       Date:  2003-12       Impact factor: 3.046

2.  Five-hundred life-saving interventions and their cost-effectiveness.

Authors:  T O Tengs; M E Adams; J S Pliskin; D G Safran; J E Siegel; M C Weinstein; J D Graham
Journal:  Risk Anal       Date:  1995-06       Impact factor: 4.000

3.  Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential.

Authors:  M Drummond; A Brandt; B Luce; J Rovira
Journal:  Int J Technol Assess Health Care       Date:  1993       Impact factor: 2.188

4.  Cost-effectiveness league tables: more harm than good?

Authors:  M Drummond; G Torrance; J Mason
Journal:  Soc Sci Med       Date:  1993-07       Impact factor: 4.634

  4 in total
  2 in total

1.  The NICE reference case requirement: more pain for what, if any, gain?

Authors:  Amiram Gafni; Stephen Birch
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.

Authors:  Maureen P M H Rutten-van Mölken; Jan B Oostenbrink; Marc Miravitlles; Brigitta U Monz
Journal:  Eur J Health Econ       Date:  2007-03-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.